Logo

Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079

Share this

Lupus Therapeutics Signs a Research Agreement with Takeda for its TAK-079

Shots:

  • Lupus Therapeutics (subsidiary of Lupus Research Alliance) collaborates with Takeda to evaluate TAK-079 (NCT03724916) in P-I clinical study assessing TAK-079 vs PBO in 24 patients with moderate to severe systemic lupus erythematosus (SLE)
  • The P-I study evaluates Takeda’s TAK-079 safety- efficacy- PK/PD and will conduct in 20 research centers including member of Lupus Therapeutics’ Lupus Clinical Investigators Network (LuCIN)
  • TAK-079 (SC) is a mAb- targets CD38 protein- reduces the immune cell expressing CD38 protein responsible for producing autoantibodies

Ref: Takeda | Image: Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions